KR20060037252A - 불안 장애의 치료 방법 - Google Patents

불안 장애의 치료 방법 Download PDF

Info

Publication number
KR20060037252A
KR20060037252A KR1020057021878A KR20057021878A KR20060037252A KR 20060037252 A KR20060037252 A KR 20060037252A KR 1020057021878 A KR1020057021878 A KR 1020057021878A KR 20057021878 A KR20057021878 A KR 20057021878A KR 20060037252 A KR20060037252 A KR 20060037252A
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
compound
lower alkyl
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057021878A
Other languages
English (en)
Korean (ko)
Inventor
히로시 가세
나오키 세노
시즈오 시오자키
미노루 고바야시
준야 가세
Original Assignee
교와 핫꼬 고교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 교와 핫꼬 고교 가부시끼가이샤 filed Critical 교와 핫꼬 고교 가부시끼가이샤
Publication of KR20060037252A publication Critical patent/KR20060037252A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020057021878A 2003-06-10 2004-06-10 불안 장애의 치료 방법 Withdrawn KR20060037252A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50904603P 2003-06-10 2003-06-10
US60/509,046 2003-06-10
US53279303P 2003-12-24 2003-12-24
US60/532,793 2003-12-24

Publications (1)

Publication Number Publication Date
KR20060037252A true KR20060037252A (ko) 2006-05-03

Family

ID=33514319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057021878A Withdrawn KR20060037252A (ko) 2003-06-10 2004-06-10 불안 장애의 치료 방법

Country Status (15)

Country Link
US (2) US8202869B2 (enExample)
EP (1) EP1631294B1 (enExample)
JP (1) JP4778894B2 (enExample)
KR (1) KR20060037252A (enExample)
CN (1) CN1787821A (enExample)
AT (1) ATE481101T1 (enExample)
AU (1) AU2004244906A1 (enExample)
BR (1) BRPI0411120A (enExample)
CA (1) CA2528710C (enExample)
CO (1) CO5640121A2 (enExample)
DE (1) DE602004029160D1 (enExample)
EA (1) EA200501924A1 (enExample)
MX (1) MXPA05013148A (enExample)
NO (1) NO20055907L (enExample)
WO (1) WO2004108137A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE039348T2 (hu) * 2002-01-28 2018-12-28 Kyowa Hakko Kogyo Kk A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
WO2008057855A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
EP2182803A4 (en) * 2007-07-23 2010-09-01 Synosia Therapeutics (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
US8609162B2 (en) * 2012-10-04 2013-12-17 Invivo Beverages Llc Integrated neuromodulation system for mood enhancement of a living human subject
CN105770563A (zh) * 2016-04-22 2016-07-20 孙建 一种治疗焦虑症的中药制剂及其制备方法
CR20230030A (es) 2018-02-27 2023-03-10 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
MX2020012376A (es) 2018-05-18 2021-03-09 Incyte Corp Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
MX2021000116A (es) 2018-07-05 2021-03-29 Incyte Corp Derivados de pirazina fusionados como inhibidores de a2a/a2b.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2022167778A1 (en) 2021-02-02 2022-08-11 Haiku Therapeutics Ltd Ebselen as adenosine receptor modulator

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612331B2 (en) * 1986-09-30 1991-07-11 Ciba-Geigy Ag 2-substituted-e-fused-(1,2,4)triazolo(1,5-c)pyrimidines pharmaceutical compositions
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2116967C (en) * 1992-07-08 2003-08-19 Fumio Suzuki Antidepressants
ES2264210T3 (es) 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
EP1116722B1 (en) * 1998-09-22 2005-01-12 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
AU4431000A (en) * 1999-05-12 2000-12-05 Fujisawa Pharmaceutical Co., Ltd. Novel use
IL152726A0 (en) * 2000-05-26 2003-06-24 Schering Corp Adenosine a2a receptor antagonists
WO2003022283A1 (en) 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
AR037243A1 (es) * 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US20030119831A1 (en) * 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102567684B1 (ko) 2023-01-10 2023-08-18 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치
KR102594242B1 (ko) 2023-01-10 2023-10-27 주식회사 웨이센 디지털 표현형 특징을 이용한 사회 불안장애 분석방법 및 장치

Also Published As

Publication number Publication date
EA200501924A1 (ru) 2006-06-30
US20060281770A1 (en) 2006-12-14
AU2004244906A1 (en) 2004-12-16
US8592420B2 (en) 2013-11-26
WO2004108137A1 (en) 2004-12-16
US20120232089A1 (en) 2012-09-13
CA2528710C (en) 2012-04-17
JP2006527264A (ja) 2006-11-30
CO5640121A2 (es) 2006-05-31
US8202869B2 (en) 2012-06-19
DE602004029160D1 (enExample) 2010-10-28
EP1631294B1 (en) 2010-09-15
NO20055907L (no) 2005-12-13
EP1631294A1 (en) 2006-03-08
CN1787821A (zh) 2006-06-14
JP4778894B2 (ja) 2011-09-21
BRPI0411120A (pt) 2006-07-18
ATE481101T1 (de) 2010-10-15
MXPA05013148A (es) 2006-03-17
CA2528710A1 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
US8592420B2 (en) Method of treating an anxiety disorder
JP6247249B2 (ja) 眼障害のためのｐｄｅ１阻害剤
JP6360025B2 (ja) 有機化合物
JP5837278B2 (ja) 新規使用
US20100009934A1 (en) Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
JP2018203760A (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
US20090047243A1 (en) Combinations for the treatment of b-cell proliferative disorders
US20090053168A1 (en) Treatments of b-cell proliferative disorders
de Souza Brocardo et al. Antidepressant-like effect of folic acid: Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway
JP2007522200A (ja) 非定型抗精神病薬とコルチコトロピン放出因子拮抗薬の治療的組合せ
Kouvelas et al. PDE5 inhibitors: in vitro and in vivo pharmacological profile
JP6696904B2 (ja) 製剤および医薬組成物
JP4838792B2 (ja) Ｐｄｅ５阻害剤のための新規の使用
TW200423932A (en) Combination of a PDE IV inhibitor and a TNF-alpha antagonist
EP2258372A1 (en) A2A antagonists for use in the treatment of motor disorders
EP1738766A1 (en) Preventive and/or therapeutic agent for disease accompanied by chronic muscle/skeleton pain
CA2496920A1 (en) Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
JP5188066B2 (ja) 薬物依存症の予防および／または治療剤
JP2003063988A (ja) Ｐｄｅ阻害剤を有効成分として含有する脊髄小脳変性症治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid